Chemistry:Lapisteride
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C29H40N2O3 |
| Molar mass | 464.650 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.
See also
References
- ↑ "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics 255 (1–2): 69–79. April 2003. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
- ↑ 2.0 2.1 "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology 10 (8): 593–595. December 2000. PMID 11125319. http://www.jle.com/medline.md?issn=1167-1122&vol=10&iss=8&page=593.
- ↑ Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. pp. 157. ISBN 978-0-11-322558-3. https://books.google.com/books?id=zruxjioUFngC&pg=PA157. Retrieved 17 November 2011.
{{Navbox
| name = Drugs used in benign prostatic hypertrophy | title = Drugs used in [[Medicine:Benign prostatic hyperpbenign prostatic hyperplasia (G04C) | state = collapsed | listclass = hlist
| group1 = 5α-Reductase inhibitors | list1 =
| group2 = Alpha-1 blockers | list2 =
| group3 = Steroidal antiandrogens | list3 =
| group4 = Herbal products | list4 =
| group5 = Others | list5 =
}}
 |  |
